What Are Summit Therapeutics Inc.'s Key Financial Figures?
| Fiscal year | FY2024 ended December 31, 2024 | FY2023 ended December 31, 2023 | FY2022 ended December 31, 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $705,000 |
| Operating income | -$226 million | -$610 million | -$72 million |
| Operating margin | n/a | n/a | -10225.4% |
| Net income | -$221 million | -$615 million | -$79 million |
| Net margin | n/a | n/a | -11174.8% |
| Operating cash flow | -$142 million | -$77 million | -$42 million |
| Capital expenditures | $139,000 | $128,000 | $624,000 |
| Free cash flow | -$142 million | -$77 million | -$42 million |
Free cash flow (operating cash flow minus capital expenditures) was -$142 million against net income of -$221 million; cash generation covered reported earnings.
What Does Summit Therapeutics Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $105 million |
|---|---|
| Long-term debt | $0 |
| Total assets | $436 million |
| Total liabilities | $47 million |
| Shareholders' equity | $389 million |
| Current ratio | 10.2x |
Balance sheet values are as of the end of fiscal 2024. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Summit Therapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001599298-25-000048 for fiscal year 2024). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Summit Therapeutics Inc.'s revenue in fiscal 2024?
Summit Therapeutics Inc. reported revenue of $0 for the fiscal year ended December 31, 2024, according to its SEC filings.
What is Summit Therapeutics Inc.'s operating margin?
Summit Therapeutics Inc. did not report operating income under the standard tag for fiscal 2024, so Swoopr does not compute an operating margin; the income statement in its 10-K shows how it presents profit.
How much free cash flow did Summit Therapeutics Inc. generate?
Operating cash flow of -$142 million less capital expenditures of $139,000 gives free cash flow of -$142 million for fiscal 2024.